Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease [RNA-Seq]

We investigated the dynamics of gene expression in blood samples of IBD patients treated with infliximab and vedolizumab and analyzed the predictive potential regarding therapy outcome. We performed a longitudinal, blood-based multi-omics study in two prospective IBD patient cohorts receiving first time infliximab therapy (discovery: 14 patients, replication: 23 patients) and one prospective IBD patient cohort receiving first time vedolizumab therapy (17 patients). Samples were collected at up to 7 timepoints (from baseline to 14 weeks after therapy induction).